Business
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
SEATTLE, June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company

About this update from Atossa Therapeutics, Inc.
SEATTLE , June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay , M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time . A live webcast of the presentation can be accessed on the Investors section of the Atossa website under "Events and Presentations" at https://investors.atossatherapeutics.com/news-events/events-presentations . The webcast will be archived for 30 days. About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/atossa-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-302470615.html SOURCE Atossa Therapeutics Inc
View stock analysis, news, and events for Atossa Therapeutics, Inc.
More from Atossa Therapeutics, Inc.
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positi...
July 28, 2026
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference ...
July 21, 2026